001     137555
005     20210129212049.0
024 7 _ |a pmid:23981784
|2 pmid
024 7 _ |a 1535-3508
|2 ISSN
024 7 _ |a 1536-0121
|2 ISSN
024 7 _ |a 10.2310/7290.2013.00056
|2 DOI
024 7 _ |a WOS:000336725000001
|2 WOS
037 _ _ |a FZJ-2013-03987
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Piroth, Marc D
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful?
260 _ _ |a Hamilton, Ont.
|c 2013
|b Decker
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1392734914_30880
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
500 _ _ |3 POF3_Assignment on 2016-02-29
520 _ _ |a Monitoring of radiochemotherapy (RCX) in patients with glioblastoma is difficult because unspecific alterations in magnetic resonance imaging with contrast enhancement can mimic tumor progression. Changes in tumor to brain ratios (TBRs) in positron emission tomography (PET) using O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) after RCX with temozolomide of patients with glioblastoma have been shown to be valuable parameters to predict survival. The kinetic behavior of 18F-FET in the tumors is another promising parameter to analyze tumor metabolism. In this study, we investigated the predictive value of dynamic 18F-FET PET during RCX of glioblastoma. Time-activity curves (TACs) of 18F-FET uptake of 25 patients with glioblastoma were evaluated after surgery (FET-1), early (7-10 days) after completion of RCX (FET-2), and 6 to 8 weeks later (FET-3). Changes in the time to peak (TTP) and the slope of the TAC (10-50 minutes postinjection) were analyzed and related to survival. Changes in kinetic parameters of 18F-FET uptake after RCX showed no relationship with survival time. In contrast, the high predictive value of changes of TBR to predict survival was confirmed. We conclude that dynamic 18F-FET PET does not provide additional prognostic information during RCX. Static 18F-FET PET imaging (20-40 minutes postinjection) appears to be sufficient for this purpose and reduces costs.
536 _ _ |a 332 - Imaging the Living Brain (POF2-332)
|0 G:(DE-HGF)POF2-332
|c POF2-332
|x 0
|f POF II
588 _ _ |a Dataset connected to juser.fz-juelich.de, PubMed,
700 1 _ |a Liebenstund, Sarah
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 2
|u fzj
700 1 _ |a Stoffels, Gabriele
|0 P:(DE-Juel1)131627
|b 3
|u fzj
700 1 _ |a Shah, N. J.
|0 P:(DE-Juel1)131794
|b 4
|u fzj
700 1 _ |a Eble, Michael J
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Coenen, Heinrich Hubert
|0 P:(DE-Juel1)131816
|b 6
|u fzj
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 7
|u fzj
773 _ _ |g Vol. 12, no. 6
|p 388-395
|n 6
|0 PERI:(DE-600)2069848-3
|t Molecular imaging
|v 12
|y 2013
|x 1535-3508
856 4 _ |z Published final document.
856 4 _ |u https://juser.fz-juelich.de/record/137555/files/FZJ-2013-03987_PV.pdf
|z Published final document.
|y Restricted
909 _ _ |p VDB
|o oai:juser.fz-juelich.de:137555
909 C O |o oai:juser.fz-juelich.de:137555
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)143792
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131627
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131816
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131777
913 2 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-579H
|2 G:(DE-HGF)POF3-500
|v Addenda
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-332
|2 G:(DE-HGF)POF2-300
|v Imaging the Living Brain
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
914 1 _ |y 2013
915 _ _ |a JCR/ISI refereed
|0 StatID:(DE-HGF)0010
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-5-20090406
981 _ _ |a I:(DE-Juel1)INM-4-20090406
981 _ _ |a I:(DE-Juel1)INM-5-20090406


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21